Tetraphase Pharmaceuticals (NASDAQ:TTPH) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Friday.
According to Zacks, “Tetraphase Pharmaceuticals, Inc. is a life science company engaged in developing and commercializing tetracycline based drugs to treat drug-resistant infectious diseases, inflammation, and cancer. Its principal products include eravacycline, an intravenous and oral antibiotic for the treatment of multi-drug resistant Gram-negative infections. The Company’s product under development includes eravacycline oral formulation, TP-834 and TP-271. Tetraphase Pharmaceuticals, Inc. is based in Watertown, Massachusetts. “
TTPH has been the topic of a number of other research reports. Needham & Company LLC restated a “hold” rating on shares of Tetraphase Pharmaceuticals in a report on Sunday, September 17th. HC Wainwright restated a “buy” rating and issued a $17.00 target price on shares of Tetraphase Pharmaceuticals in a report on Tuesday, December 5th. BMO Capital Markets raised their target price on Tetraphase Pharmaceuticals from $13.00 to $24.00 and gave the company an “outperform” rating in a report on Wednesday, October 4th. Finally, ValuEngine lowered Tetraphase Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Friday, December 1st. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and four have given a buy rating to the company’s stock. The company presently has an average rating of “Hold” and an average price target of $15.15.
Tetraphase Pharmaceuticals (NASDAQ:TTPH) last posted its earnings results on Thursday, November 2nd. The biopharmaceutical company reported ($0.63) earnings per share for the quarter, meeting the Zacks’ consensus estimate of ($0.63). Tetraphase Pharmaceuticals had a negative return on equity of 88.27% and a negative net margin of 1,382.33%. The company had revenue of $4.10 million for the quarter, compared to analyst estimates of $1.59 million. During the same quarter last year, the company earned ($0.58) earnings per share. The company’s revenue for the quarter was up 355.6% on a year-over-year basis. equities analysts forecast that Tetraphase Pharmaceuticals will post -2.88 earnings per share for the current fiscal year.
In other Tetraphase Pharmaceuticals news, Director L Patrick Gage purchased 3,880 shares of the company’s stock in a transaction that occurred on Wednesday, November 29th. The shares were acquired at an average cost of $6.45 per share, for a total transaction of $25,026.00. Following the completion of the acquisition, the director now owns 38,880 shares of the company’s stock, valued at approximately $250,776. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Jacques Dumas sold 8,750 shares of Tetraphase Pharmaceuticals stock in a transaction on Tuesday, October 31st. The stock was sold at an average price of $6.03, for a total value of $52,762.50. Following the sale, the insider now owns 8,750 shares in the company, valued at $52,762.50. The disclosure for this sale can be found here. 5.50% of the stock is owned by company insiders.
A number of institutional investors have recently modified their holdings of the stock. Cubist Systematic Strategies LLC bought a new stake in Tetraphase Pharmaceuticals during the third quarter worth $195,000. California State Teachers Retirement System increased its position in Tetraphase Pharmaceuticals by 20.1% in the third quarter. California State Teachers Retirement System now owns 80,471 shares of the biopharmaceutical company’s stock worth $550,000 after buying an additional 13,451 shares during the last quarter. Dimensional Fund Advisors LP increased its position in Tetraphase Pharmaceuticals by 32.7% in the third quarter. Dimensional Fund Advisors LP now owns 1,461,807 shares of the biopharmaceutical company’s stock worth $9,998,000 after buying an additional 360,552 shares during the last quarter. Schwab Charles Investment Management Inc. increased its position in Tetraphase Pharmaceuticals by 67.4% in the third quarter. Schwab Charles Investment Management Inc. now owns 217,079 shares of the biopharmaceutical company’s stock worth $1,485,000 after buying an additional 87,398 shares during the last quarter. Finally, JPMorgan Chase & Co. purchased a new stake in Tetraphase Pharmaceuticals in the third quarter worth $7,915,000. Institutional investors and hedge funds own 58.15% of the company’s stock.
About Tetraphase Pharmaceuticals
Tetraphase Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company uses its chemistry technology to create antibiotics for multidrug-resistant infections. The Company is developing its lead product candidate, eravacycline, a fully synthetic tetracycline derivative, as a spectrum intravenous (IV) and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multidrug-resistant infections, including multidrug-resistant gram-negative infections.
Receive News & Ratings for Tetraphase Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tetraphase Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.